Advertisement

Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-α/anti-Fas antibody and chemotherapeutic drugs or toxins

  • B. Bonavida
  • J. T. Safrit
  • H. Morimoto
  • Y. Mizutani
  • S. Yonehara
  • J. S. Berek

Abstract

Current conventional therapies in the treatment of neoplastic diseases consist of surgery, chemotherapy, radiotherapy and combination therapy. While these forms of treatment have resulted in cures and prolonged survival, recurrent tumors and metastases continue to be very common. Treatment of these recurrent tumors has posed a major challenge to oncologists since these tumors become refractory to chemotherapeutic drugs and metastases are not amenable to surgery or radiotherapy. Thus, the development of tumor cell resistance to cytotoxic drugs has provoked the search for new means to overcome resistance. During the last few years, a surge of new approaches in cancer therapy has emerged that include biological response modifiers to boost the immune response, the use of activated cytotoxic cells such as LAK and TIL and the preparation of ’magic bullets’ consisting of targeted antibody-drug/toxin conjugates, the use of recombinant cytokines (e.g. TNF-α, IFN-γ, IL-2 etc.) and more recently, genetic engineering techniques to modify tumor cells or lymphocytes. Furthermore, new agents to reverse the multidrug resistance phenotype have been considered.

Keywords

Chemotherapeutic Drug Ovarian Carcinoma Cell Line Overcome Drug Resistance Target Cell Lysis Human Ovarian Carcinoma Cell Line 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Safrit, J., Tsuchitani, T., Zighelboim, J. and Bonavida, B. (1992) Hierarchy of sensitivity and resistance of tumor cells to cytotoxic effector cells, cytokines, drugs and toxins. Cancer Immunol. Immunother., 34, 321–8.PubMedCrossRefGoogle Scholar
  2. 2.
    Carswell, E.A., Old L.J., Kassel, R.L. et al (1975) An endotoxin-induced serum factor that causes necrosis in tumors. Proc. Natl Acad. Sci. USA, 72, 3666–70.PubMedCrossRefGoogle Scholar
  3. 3.
    Sherman, M.L., Spriggs, D.R., Arthur, K.A. et al (1988) Recombinant human tumor necrosis factor administered as a five days infusion in cancer patients: phase I toxicity and effects on lipid metabolism. J. Clin. Oncol, 6, 344–50.PubMedGoogle Scholar
  4. 4.
    Balkwill, D.E., Ward, B.C., Woodie, E. et al (1987) Therapeutic potential of tumor necrosis factor α and γ interferon in experimental human ovarian cancer. Cancer Res., 47, 4755–8.PubMedGoogle Scholar
  5. 5.
    Bonavida, B., Tsuchitani, T., Zighelboim, J., et al (1990) Synergy is documented in vitro with low dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells. Gynecol Oncol, 38, 333–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Riordan, J.R. and Ling, V. (1985) Genetic and biochemical characterization of multidrug resistance. Pharmacol Ther., 28, 51–75.PubMedCrossRefGoogle Scholar
  7. 7.
    Horio, M., Gottesman, N.M. et al (1988) ATP- dependent transport of vinblastine vesicles from human multidrug-resistant cells. Proc. Natl Acad. Sci. USA, 85, 3580–4.PubMedCrossRefGoogle Scholar
  8. 8.
    Schmid, D.S., Honung, R., McGrath, K.M. et al (1987) Target cell DNA fragmentation is mediated by lymphotoxin and TNF-α. Lymphokine Res., 6,195–202.PubMedGoogle Scholar
  9. 9.
    Safrit, J.T., Berek, J.S. and Bonavida, B. (1992) Sensitivity of drug resistant human ovarian tumor cell lines to combined effects of tumor necrosis factor (TNF-α) and doxorubicin. Failure of the combination to modulate the MDR phenotype. Gynecol. Oncol., 48, 214–20.CrossRefGoogle Scholar
  10. 10.
    Spriggs, D., Imanura, K., Rodriguez, D. et al. (1987) Induction of tumor necrosis factor expression and resistance in a human breast tumor cell line. Proc. Natl. Acad. Sci. USA, 84, 6563.PubMedCrossRefGoogle Scholar
  11. 11.
    Safrit, J.T., Belldegrun, A. and Bonavida, B. (1993) Sensitivity of human renal cell carcinoma lines to TNF, adriamycin and combination: role of TNF-mRNA induction in overcoming resistance. J. Urol., 149, 1202–8.PubMedGoogle Scholar
  12. 12.
    Wong, G.H.W., Elwell, J.H., Oberly, L.W. et al. (1989) Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell, 58, 923.PubMedCrossRefGoogle Scholar
  13. 13.
    Mizutani, Y. and Bonavida, B. (1993) Overcoming CDDP resistance of human ovarian tumor cells by combination treatment with CDDP and TNF-α. Cancer, 72, 809–18.PubMedCrossRefGoogle Scholar
  14. Coleman, C.N., Glove, D.J. and Turrisi, A.T. (1990) Radiation and chemotherapy sensitizers and protectors. In Cancer Chemotherapy, (eds B.A. Chabner and J.M. Collins), J.B. Lippincott, Philadelphia, pp. 424–48.Google Scholar
  15. 15.
    McGown, A.T. and Gox, B.W. (1986) A proposed mechanism of resistance to cyclophosphamide and phosphoramide mustard in a Yoshida cell line in vitro. Cancer Chemother. Pharmacol, 17,223–9.Google Scholar
  16. 16.
    Mans, D.R.A., Schuurhuis, G.J., Treskes, M. et al (1992) Modulation by D,L-buthionine-S, R-sulphoximine of etoposide cytotoxicity on human non-small cell lung, ovarian and breast carcinoma cell lines. Eur. J. Cancer, 28, 1447–52.CrossRefGoogle Scholar
  17. 17.
    Chang, M.P., Bramhall, J., Graves, S. et al. (1989) Internucleaosomal DNA cleavage preceded diphtheria toxin-induced cytolysis. Evidence that cell lysis is not a simple consequence of translation inhibition. J. Biol. Chem., 264,15261.PubMedGoogle Scholar
  18. 18.
    Morimoto, H., Safrit, J.T. and Bonavida, B. (1991) Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines, J. Immunol, 147,2609.PubMedGoogle Scholar
  19. 19.
    Morimoto, H. and Bonavida, B. (1992) Diphtheria-toxin and Pseudomonas, a toxin- mediated apoptosis: ADP-ribosylation of EF-2 is required for DNA fragmentation and cell lysis and synergy with tumor necrosis factoren. J. Immunol, 149,2089–94.PubMedGoogle Scholar
  20. 20.
    Yonehara, S., Ishii, A. and Yonehara, M. (1991) A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med., 169, 1747–56.CrossRefGoogle Scholar
  21. 21.
    Reichman, B., Markman, M., Inotti, N. et al (1989) Phase I trial of intraperitoneal recombinant tumor necrosis factor. Proc. Am. Soc. Clin. Oncol, 8,64.Google Scholar
  22. 22.
    Raeth, U., Schmid, H., Karck, U. et al (1991) Phase II trial of recombinant human tumor necrosis factor in patients with malignant ascites from ovarian carcinomas and non-ovarian tumors with intraperitoneal spread. Proc. Am. Soc. Clin. Oncol, 10, 187.Google Scholar
  23. 23.
    Abbruzzese, J.L., Levin, B., Ajani, J.A. et al (1989) Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res., 49,4057–61.PubMedGoogle Scholar
  24. 24.
    Schiller, J.H., Alberti, D.B., Arzoomanian, R.Z. et al (1990) Phase I trial of combination of recombinant gamma interferon and recombinant tumor necrosis factor alpha. Proc. Am. Assoc. Cancer Res., 31,183.Google Scholar
  25. 25.
    Mcintosh, J.K., Mule, J.J., Krosnick, J.A. et al (1989) Combination cytokine immuno-therapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.Cancer Res., 49, 1408–14.PubMedGoogle Scholar
  26. 26.
    Yang, S.C., Owen, S.L., Mendiguren, R.A. et al (1990) Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha, J. Thorac. Cardiovasc. Surg., 99, 8–12.PubMedGoogle Scholar
  27. 27.
    Alexander, R.B., Nelson, W.G. and Coffey, D.S (1987) Synergistic enhancement by tumor necrosis factor ofin vitro cytotoxicity from chemotherapeutic drugs targeted at DNA topoisomerase II. Cancer Res.,47, 2403–6.PubMedGoogle Scholar
  28. 28.
    Orr, D., Oldham, R., Lewis, M. et al (1989) Phase I study of the sequenced administrationD. of etoposide and recombinant tumor necrosis factor in patients with advanced malignancy, Proc. Am. Sac. Clin. Oncol, 8, 741.Google Scholar

Copyright information

© Chapman & Hall 1995

Authors and Affiliations

  • B. Bonavida
  • J. T. Safrit
  • H. Morimoto
  • Y. Mizutani
  • S. Yonehara
  • J. S. Berek

There are no affiliations available

Personalised recommendations